• World
    • Africa
    • Asia Pacific
    • Central & South Asia
    • Europe
    • Latin America & Caribbean
    • Middle East & North Africa
    • North America
  • Coronavirus
  • Politics
    • US Election
    • US politics
    • Joe Biden
    • Brexit
    • European Union
    • India
    • Arab world
  • Economics
    • Finance
    • Eurozone
    • International Trade
  • Business
    • Entrepreneurship
    • Startups
    • Technology
  • Culture
    • Entertainment
    • Music
    • Film
    • Books
    • Travel
  • Environment
    • Climate change
    • Smart cities
    • Green Economy
  • Global Change
    • Education
    • Refugee Crisis
    • International Aid
    • Human Rights
  • International Security
    • ISIS
    • War on Terror
    • North Korea
    • Nuclear Weapons
  • Science
    • Health
  • 360 °
  • The Interview
  • In-Depth
  • Insight
  • Quick Read
  • Video
  • Podcasts
  • Interactive
  • My Voice
  • About
  • FO Store
Sections
  • World
  • Coronavirus
  • Politics
  • Economics
  • Business
  • Culture
  • Sign Up
  • Login
  • Publish

Make Sense of the world

Unique insight from 2,000+ contributors in 80+ Countries

Close

Can an Indian Family Save Humanity From COVID-19?

In the face of a pandemic, an Indian family attempts to do what is beyond the scope of the cultures of governments and pharmaceutical giants.
By Peter Isackson • Aug 03, 2020
Serum Institute, coronavirus vaccine, COVID 19 vaccine, Oxford University vaccine, AstraZeneca, Adar Poonawalla, Poonawalla family, Indian pharmaceutical companies, coronavirus news, Peter Isackson

© Siam Pukkato

As the world continues to endure the uncertainty and anguish bought by the invisible threat both to individual lives and the global economy, many politicians cling to the idea that once a vaccine against the COVID-19 disease is found, the return to normalcy will at last become possible. Governments will be willing to pay fortunes for the vaccine that works. And those who create an effective vaccine will earn fortunes. From a pharmaceutical point of view, health has no price. For many people, it has a cost. This is especially true in the US, the nation the most affected by the novel coronavirus that causes COVID-19 and a place where health care is ensured according to the logic of a lottery.

The US government set up Operation Warp Speed to fund research and development of a vaccine. On July 31, Reuters reported that the “US government will pay $2.1 billion to Sanofi SA and GlaxoSmithKline Plc for COVID-19 vaccines to cover 50 million people and to underwrite the drugmakers’ testing and manufacturing.” Presumably, the firms will be able to make a further profit from selling the resulting vaccines privately. This is a lucrative business.


The Latest Version of Russiagate

READ MORE


New York Times reporter Jeffrey Gettleman cites a very different initiative taken privately by a prosperous Indian company. The Serum Institute “announced a plan to make hundreds of millions of doses of an unproven inoculation” without a government grant. The Times calls it “a gamble” because there is no guarantee the vaccine being developed will be effective.

Normally, in the field of public health, wealthy companies don’t gamble, but Gettleman highlights a difference with the Serum Institute. “Serum is distinct from all other major vaccine producers in an important way,” he writes. “Like many highly successful Indian businesses, it is family-run. It can make decisions quickly and take big risks, like the one it’s about to, which could cost the family hundreds of millions of dollars.”

Here is today’s 3D definition:

Family-run:

In the mythical past of capitalism, the traditional model for startup businesses that heroically struggled to supply solutions to perceived needs and work on a human scale until it became the norm for them to be taken over by non-heroic investors driven only by the firm’s capacity to satisfy their own greed

Contextual Note

Today’s pharmaceutical companies in the West represent the true spirit of modern capitalism, as defined by fabled theoreticians Friedrich von Hayek and Milton Friedman, who modeled its ethics of justified greed. The basic strategic principle consists of securing a monopolistic position to propose unique products at the highest possible price to customers who can afford them. That means the wealthy will always be served first.

Because pharmaceutical companies promise to improve public health, their executives are skilled at getting grants from public bodies to fund their research. Why should the firms take the risk of investing their own cash? But when publicly-funded research results in a viable product, the law of maximum profit means that it’s the company’s economic health, not public health that will benefit. For pharma executives, the role of governments is to gamble while they rake in the rewards.

Embed from Getty Images

Serum has decided to make an honest gamble by investing in its industrial capacity to serve the public, without government help. Its ultimate impact on public health will prove even more essential than creating a new product. It will supply the product to those who need it, basically at cost. The company is tooling up at its own expense to ensure the industrialization and rapid distribution of what many recognize as the most promising vaccine now being developed by an Oxford University laboratory in partnership with the pharmaceutical giant, AstraZeneca.

The young CEO of Serum, Adar Poonawalla, has dared to violate both sacred principles of today’s profit-spinning capitalism: get others to put up the money and focus on maximizing profits through sales. Instead of appealing only to those who can afford it, the company’s vision targets those who need it. Poonawalla promises to “split the hundreds of millions of vaccine doses he produces 50-50 between India and the rest of the world, with a focus on poorer countries,” The Times reports. Profits will come later because “during the pandemic they will charge an amount that is no more than its production costs.”

The Poonawallas are worth more than $5 billion. How could intelligent billionaires be so addle-brained as to make investments that “could cost the family hundreds of millions of dollars” only to sell the product at cost? Shouldn’t this be seen as an act of betrayal of the billionaire class and the ethical rules established by von Hayek and Friedman?

The Wire sums up its takeaway from Gettleman’s story: “[T]he New York Times also reported that India’s Serum Institute is uniquely positioned because it is rich and isn’t beholden to shareholders.” Can it be that, contrary to Senator Bernie Sanders’ bold and philosophically reasonable assertion that “billionaires should not exist,” the Poonawallas have provided proof that at least two billionaires — father and son — should exist? 

Historical Note

The Poonawallas are exceptions, but only because they have managed to remain a family business. Despite its size, the Serum Institute is a relic of the history of capitalism as it emerged in the 19th century before being overtaken in the 20th century by convergent financial and market forces. By laying bare the working principles of capitalism, Karl Marx himself may have helped capitalists to understand that the key to maximum profit was maximum clout. To make sense today, any serious project must follow the logic and “science of venture capital” or private equity. If the family business provided the old mythical foundation of capitalist venture, the new and equally romanticized model supposes two geniuses who build their idea in a garage before inviting in the investors who sense the promise of a monopoly that will eventually be gobbled up by a very rich company or go public.

In some respects, the Poonawalla family has managed to conform to the modern model of capitalism. “Adar Poonawalla acknowledged that his family was better known for ‘being seen in some fancy car or a jet or whatever,’ than making lifesaving vaccines,” The Times reports. But that is more about how class is perceived than economic reality. It has special meaning in India with its persistent caste ideology. In every society, the super-rich must decide how to show off or hide their wealth. Westerners give more importance to vaunting their capacity to manage rather than flaunt it. That correlates with the fact that India has more family-run businesses than most other countries.

Only a family-run business could dare to announce this strategy: “After the pandemic passes, Mr. Poonawalla expects that he will be able to sell the vaccine at a profit — if it works — but his biggest concern is the near term and covering his cash flow,” Jeffrey Gettleman writes.

logo

Make Sense of the World

Unique insight from 2,000+ contributors in 80+ Countries

Make Sense of the World
Unique insights from 2000+ contributors in 80+ countries

It is true that for two decades, American billionaire Jeff Bezos violated the logic of traditional investors by refusing to aim for profitability. He kept Amazon focused on market positioning, the hope of achieving monopoly status. It worked, as has now become obvious. His company can no longer avoid making a profit, even when he continues to try.

The Times article sums up the unorthodox capitalist logic of Serum in these terms: “Mr. Poonawalla said he felt an obligation to take this risk.” In his own words, “We just felt that this was our sort of moment.” 

The risk is real. Family businesses are more fragile than investor-led companies. The ultimate tragedy of the story may still be in the offing. In the end, the family may have to compromise the liberty that has allowed it to step forward with this project. The company’s and the family’s finances alone will be strained beyond capacity even in the case of success. “For the first time, the Poonawallas say they are considering turning to sovereign wealth or private equity funds for help,” reports Gettleman.

Peering into the future, the article then evokes the possibility of seeking “financial help from the Bill & Melinda Gates Foundation … or maybe the Indian government.” It is the iron law of global capitalism. Every dream of continued independence is doomed to end someday. It is downright Darwinian. That is the world even rich Indian family businesses interested in responding to humanity’s needs are condemned to live in and adapt to.

*[In the age of Oscar Wilde and Mark Twain, another American wit, the journalist Ambrose Bierce, produced a series of satirical definitions of commonly used terms, throwing light on their hidden meanings in real discourse. Bierce eventually collected and published them as a book, The Devil’s Dictionary, in 1911. We have shamelessly appropriated his title in the interest of continuing his wholesome pedagogical effort to enlighten generations of readers of the news. Click here to read more of The Daily Devil’s Dictionary on Fair Observer.]

The views expressed in this article are the author’s own and do not necessarily reflect Fair Observer’s editorial policy.

Share Story
CategoriesBusiness, Central & South Asia, Coronavirus, Health, India News, Insight, Science, World News TagsAdar Poonawalla, AstraZeneca, coronavirus news, coronavirus vaccine, COVID 19 vaccine, Indian pharmaceutical companies, Oxford University vaccine, Peter Isackson, Poonawalla family, Serum Institute
Join our network of more than 2,000 contributors to publish your perspective, share your story and shape the global conversation. Become a Fair Observer and help us make sense of the world.

Post navigation

Previous PostPrevious How Will the UAE Cope With Growing Environmental Insecurity?
Next PostNext How K-Pop Has Evolved
Subscribe
Register for $9.99 per month and become a member today.
Publish
Join our community of more than 2,500 contributors to publish your perspective, share your narrative and shape the global discourse.
Donate
We bring you perspectives from around the world. Help us to inform and educate. Your donation is tax-deductible.

Explore

  • About
  • Authors
  • FO Store
  • FAQs
  • Republish
  • Privacy Policy
  • Terms of Use
  • Contact

Regions

  • Africa
  • Asia Pacific
  • Central & South Asia
  • Europe
  • Latin America & Caribbean
  • Middle East & North Africa
  • North America

Topics

  • Politics
  • Economics
  • Business
  • Culture
  • Environment
  • Global Change
  • International Security
  • Science

Sections

  • 360°
  • The Interview
  • In-Depth
  • Insight
  • Quick Read
  • Video
  • Podcasts
  • Interactive
  • My Voice

Daily Dispatch


© Fair Observer All rights reserved
We Need Your Consent
We use cookies to give you the best possible experience. Learn more about how we use cookies or edit your cookie preferences. Privacy Policy. My Options I Accept
Privacy & Cookies Policy

Edit Cookie Preferences

The Fair Observer website uses digital cookies so it can collect statistics on how many visitors come to the site, what content is viewed and for how long, and the general location of the computer network of the visitor. These statistics are collected and processed using the Google Analytics service. Fair Observer uses these aggregate statistics from website visits to help improve the content of the website and to provide regular reports to our current and future donors and funding organizations. The type of digital cookie information collected during your visit and any derived data cannot be used or combined with other information to personally identify you. Fair Observer does not use personal data collected from its website for advertising purposes or to market to you.

As a convenience to you, Fair Observer provides buttons that link to popular social media sites, called social sharing buttons, to help you share Fair Observer content and your comments and opinions about it on these social media sites. These social sharing buttons are provided by and are part of these social media sites. They may collect and use personal data as described in their respective policies. Fair Observer does not receive personal data from your use of these social sharing buttons. It is not necessary that you use these buttons to read Fair Observer content or to share on social media.

 
Necessary
Always Enabled

These cookies essential for the website to function.

Analytics

These cookies track our website’s performance and also help us to continuously improve the experience we provide to you.

Performance
Uncategorized

This cookie consists of the word “yes” to enable us to remember your acceptance of the site cookie notification, and prevents it from displaying to you in future.

Preferences
Save & Accept